NRG-GY004: Amendment 11, version date: August 15, 2019
Protocol Title: “A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
NCI Version Date: 08/15/2019
Study Chair: Joyce Liu, M.D., (617) 632-8927; email: email@example.com
AMENDMENT 11 The NCI Central Institutional Review board (CIRB) has approved this protocol amendment. Protocol documents can be obtained from the CIRB tab of the CTSU website.
Documentation of IRB approval of Amendment 11 (PVD 08/15/2019) must be submitted to the CTSU Regulatory Office.
For details, please review the summary of changes.
Four Penn Center
1600 JFK Blvd.
, Philadelphia, PA, 19103